What medications do you prioritize or avoid in Parkinson’s Disease-related psychosis and behavioral disturbance?

From an evidence-based perspective, clozapine continues to have the most solid support for its efficacy in Parkinson's disease-related psychosis. Pimavanserin has FDA approval (albeit with some mixed data) specifically for this indication. Quetiapine and olanzapine are perhaps the most frequently used, but least supported medications for this indication.

From a practical point of view, pimavanserin is inaccessible to many patients due to cost and insurance coverage. Clozapine might be an undesirable medication to use in a first trial due to metabolic side effects, the inconvenience of blood monitoring, and anticholinergic side effects which, while perhaps desirable for young patients with Parkinson's disease, poses a delirium risk for patie...

1. Clozapine (Clozaril): This is often considered the gold standard due to its efficacy and relatively low risk of worsening motor symptoms.
2. Quetiapine (Seroquel): This may be effective, but its use is limited due to concerns about increased risk of cognitive decline.
3. Pimavanserin (Nuplazid): FDA-approved specifically for Parkinson's disease psychosis, with fewer motor side effects.

Other options:

1. Olanzapine (Zyprexa): This may be used but with caution due to potential motor side effects.
2. Risperidone (Risperdal): This is not typically recommended due to the high risk of worsening motor symptoms.
3. Aripiprazole (Abilify): It may be considered, but its efficacy and safety profile in Parkinson's disease psychosis are less established.

I have found rivastigmine to help with psychotic symptoms in PD and DLB. I would consider mild symptoms before or concurrent with pimavanserin or low-dose quetiapine. Pimavanserin may take 1-2 months to take full effect, just something to keep in mind. I have no personal experience with clozapine, but textbooks and board exams may suggest it as a first line, which requires blood monitoring and being in a database in the US.